trial
as of 2026-07-01Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
NCTId NCT05838625
at a glance
Phase 3 · Completed
Enrollment 464 (actual)
Sponsored by Click Therapeutics, Inc.
Primary completion 2025-06-20
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
464 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2023-03-31
Primary completion
2025-06-20
Eligibility
ALL · 18 Years
Interventions & indications
Drugs
Indications
Sponsors
Click Therapeutics, Inc.Lead Sponsor
Boehringer IngelheimCollaborator
Investigators
1
Viveca Livezey, MDStudy Director
Sites
54 total
Chandler, United StatesPhoenix, United StatesAnaheim, United StatesCulver City, United StatesGarden Grove, United StatesLa Habra, United StatesLong Beach, United StatesLos Angeles, United StatesNewport Beach, United StatesOceanside, United StatesOrange, United StatesSan Bernardino, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
464
Phase
PHASE3
Primary Completion Date
2025-06-20
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
indication
indication
investigator
person